Gabapentin Capsule
Product Images NDC 72865-252

Product Visual Gallery

This gallery contains 25 technical images submitted to the FDA as part of the official labeling for Gabapentin (NDC 72865-252). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Xlcare Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

100-180 (100 180)

XLcare is a medication in the form of Gabapentin capsules. Each package contains 180 capsules. It is a prescription-only medication and should be stored at controlled room temperature between 7°F and 86°F. The medication is manufactured by SocantPramacaicas and XUCare pharmaceutical companies. For dosage and usage information, refer to the complete prescribing information provided in the package.*

FDA Label Image

100-270 (100 270)

Not available*

FDA Label Image

100-500 (100 500)

FDA Label Image

100-90 (100 90)

FDA Label Image

300-180 (300 180)

Store a1 257 (17 excursions pernite XLcare Detween 15° 10 30°C (59° 085 [see P Aol ¢ Contoted Room Teaperatur] NDO72865-253-18 Dponin ot U9 ch et contaers DosAGe anD Use ‘oo package nsert o full proscring formation Gabapentin - sesicr s sen Capsules, USP jisuee,. . Contal i, Y 11722 200 mg [ A T 180 Capsules Rx Only Rev: 0623*

FDA Label Image

300-270 (300 270)

FDA Label Image

300-30 (300 30)

FDA Label Image

300-500 (300 500)

FDA Label Image

300-60 (300 60)

FDA Label Image

300-90 (300 90)

Store at 25 degrees Celsius (77 degrees Fahrenheit) with excursions permitted. XLcare should be stored between 15-30 degrees Celsius (59-86 degrees Fahrenheit). This is a controlled temperature product. The product with the code DO 72865-253-00 is to be dispensed in the US, in child-resistant containers. The dosage and usage instructions can be found in the package insert. The product is Gabapentin - Capsules, USP, with a strength of 200 mg. It contains 90 capsules and is for prescription use only. The revision date for the product is 0623.*

FDA Label Image

400-270 (400 270)

FDA Label Image

400-500 (400 500)

FDA Label Image

400-90 (400 90)

FDA Label Image

Equation (Equ)

This text appears to be a formula for calculating something related to age, weight, and serum creatinine levels. Specifically, it involves multiplying the individual's age (measured in years) by their weight (measured in kilograms), and then multiplying their serum creatinine level (measured in mg/dL) by 72. Additionally, there is a note indicating that for female patients, the result should be multiplied by 0.85. However, without more context or information, it is difficult to determine the exact purpose or application of this calculation.*

FDA Label Image

Fig 1 (Fig 1)

FDA Label Image

Fig 2 (Fig 2)

FDA Label Image

Fig 3 (Fig 3)

FDA Label Image

Fig 4 (Fig 4)

FDA Label Image

Structure (Struct)

FDA Label Image

Table 1 (Tab 1)

FDA Label Image

Table 2 (Tab 2)

FDA Label Image

Table 3 (Tab 3)

FDA Label Image

Table 4 (Tab 4)

FDA Label Image

Table 5 (Tab 5)

This is a description of adverse reactions observed in a placebo-controlled add-on trial in pediatric epilepsy patients aged 3 to 12 years. The text provides information on the number of patients who experienced different adverse reactions while taking Gabapenin® as compared to a placebo. The adverse reactions are categorized by body system, such as body as a whole, digestive system, nervous system, and respiratory system. Some of the adverse reactions mentioned include viral infection, fever, increased weight, fatigue, nausea and/or vomiting, somnolence, hostility, emotional lability, dizziness, and respiratory infections. The text also mentions that these adverse reactions were observed in patients who were receiving background antiepileptic drug therapy.*

FDA Label Image

Tab 6 (Tab 6)

This text provides information on controlled PHN studies involving the medication Gabapentin. It lists the duration of the studies, dosages given to patients, and the number of participants in each study. However, the text does not provide specific values for the duration, dosages, and number of patients. Therefore, the information is not available.*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.